Cellular immunotherapy for medulloblastoma

Schakelaar, Michael Y; Monnikhof, Matthijs; Crnko, Sandra; Pijnappel, Emma; Meeldijk, Jan; Broeke, Toine ten; Bovenschen, Niels

doi:10.1093/neuonc/noac236

Cited by 9 publications

(4 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, many efforts have been made to overcome limitations [ 26 ]. Early-phase clinical trials of chimeric antigen receptor T-cell therapy targeting NKG2DL, GD2, HER2, EGFR, G7-H3, natural kille (NK) cells, and dendritic cell therapy are also ongoing [ 61 62 ].…”

Section: Treatmentmentioning

confidence: 99%

Medulloblastoma: Current Perspectives and Recent Advances

Choi

2023

Brain Tumor Res Treat

View full text Add to dashboard Cite

Medulloblastoma is the most common embryonal tumor of the central nervous system in childhood. Combined multimodality approaches, including surgery, radiation, and chemotherapy, have improved the outcome of medulloblastoma. Advances in genomic research have shown that medulloblastoma is not a biologically or clinically discrete entity. Previously, the risk was divided according to histology, presence of metastasis, degree of resection, and age at diagnosis. Through the development of integrated genomics, new biology-based risk stratification methods have recently been proposed. It is also important to understand the genetic predisposition of patients with medulloblastoma. Therefore, treatment goal aimed to improve the survival rate with minimal additional adverse effects and reduced long-term sequelae. It is necessary to incorporate genetic findings into the standard of care, and clinical trials that reflect this need to be conducted.

show abstract

Section: Treatmentmentioning

confidence: 99%

Medulloblastoma: Current Perspectives and Recent Advances

Choi

2023

Brain Tumor Res Treat

View full text Add to dashboard Cite

show abstract

“…The goal of immunotherapy is to stimulate and enhance the body's natural defense system in order to slow and eventually eliminate tumor growth. Over the past 20 years, numerous immunotherapeutics have been developed for cancer treatment that have undergone intensive preclinical and clinical testing; some of these therapies have received FDA approval and are currently being used as part of innovative therapeutic regimens [83,84].…”

Section: Tumor Microenvironment and Immunotherapiesmentioning

confidence: 99%

“…that promotes immunosuppression [68,81,82]. Elevated levels of Tregs have been detected in the peripheral blood of patients following standard therapy, presenting a potential new strategy in the treatment of medulloblastomas [83]. However, the interaction between TAMs, TILs, other cell types, and secreted molecules in the medulloblastoma microenvironment has not been extensively studied.…”

Section: Tumor Microenvironment and Immunotherapiesmentioning

confidence: 99%

Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment

Rechberger,

Toll,

Vanbilloen

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Medulloblastoma is the most common malignant brain tumor in children. Over the last few decades, significant progress has been made in revealing the key molecular underpinnings of this disease, leading to the identification of distinct molecular subgroups with different clinical outcomes. In this review, we provide an update on the molecular landscape of medulloblastoma and treatment strategies. We discuss the four main molecular subgroups (WNT-activated, SHH-activated, and non-WNT/non-SHH groups 3 and 4), highlighting the key genetic alterations and signaling pathways associated with each entity. Furthermore, we explore the emerging role of epigenetic regulation in medulloblastoma and the mechanism of resistance to therapy. We also delve into the latest developments in targeted therapies and immunotherapies. Continuing collaborative efforts are needed to further unravel the complex molecular mechanisms and profile optimal treatment for this devastating disease.

show abstract

“…Therapeutic targeting of the interaction between tumor and microenvironment is the most promising treatment method. Tumor-infiltrating immune cells, principally lymphocytes and myeloid cells, have been shown to be of prognostic relevance and predictive for response to chemotherapy in various tumors [ 104 , 109 – 113 ]. Previous studies have described the characteristics of immune microenvironment of MBs by conventional methods.…”

Section: Introductionmentioning

confidence: 99%

Heterogeneity and tumoral origin of medulloblastoma in the single-cell era

Sheng,

Li,

Zeng

et al. 2024

Oncogene

View full text Add to dashboard Cite

Medulloblastoma is one of the most common malignant pediatric brain tumors derived from posterior fossa. The current treatment includes maximal safe surgical resection, radiotherapy, whole cranio-spinal radiation and adjuvant with chemotherapy. However, it can only limitedly prolong the survival time with severe side effects and relapse. Defining the intratumoral heterogeneity, cellular origin and identifying the interaction network within tumor microenvironment are helpful for understanding the mechanisms of medulloblastoma tumorigenesis and relapse. Due to technological limitations, the mechanisms of cellular heterogeneity and tumor origin have not been fully understood. Recently, the emergence of single-cell technology has provided a powerful tool for achieving the goal of understanding the mechanisms of tumorigenesis. Several studies have demonstrated the intratumoral heterogeneity and tumor origin for each subtype of medulloblastoma utilizing the single-cell RNA-seq, which has not been uncovered before using conventional technologies. In this review, we present an overview of the current progress in understanding of cellular heterogeneity and tumor origin of medulloblastoma and discuss novel findings in the age of single-cell technologies.

show abstract

Cellular immunotherapy for medulloblastoma

Cited by 9 publications

References 93 publications

Medulloblastoma: Current Perspectives and Recent Advances

Medulloblastoma: Current Perspectives and Recent Advances

Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment

Heterogeneity and tumoral origin of medulloblastoma in the single-cell era

Contact Info

Product

Resources

About